Background {#Sec1}
==========

In 2010, deaths due to cardiovascular disease (CVD) in the Asia-Pacific region accounted for 14% of all deaths and 48% of CVD-related deaths worldwide \[[@CR1]\]. The share of CVD-related deaths in all-cause deaths in the Asia-Pacific region has also been rising over time - from 40% in 1990 to 48% in 2010 \[[@CR1],[@CR2]\]. The most recent figures from the Institute for Health Metrics and Evaluation in 2010 also show that countries of the Asia-Pacific Region experienced 52% of global disability-adjusted life years (DALYs) lost due to CVD (World Health Organization (WHO)) \[[@CR2],[@CR3]\].

The growing incidence of CVD implies adverse economic consequences for countries in the region \[[@CR2],[@CR4]\]. Thus, smoking in China was estimated to impose an economic burden of US\$28.9 billion in 2008, with medical treatment costs rising by 154% and indirect costs (such as foregone productivity) by 376% between 2000 and 2008 \[[@CR5]\]. It has also been projected that in the absence of preventive action, CVD could cost Pakistan US\$31 billion and India US\$237 billion by 2015 in lost GDP \[[@CR6]\]. A recent study \[[@CR7]\] suggests that heart disease significantly increased out of pocket health spending, reduced labour force participation rate and increased indebtedness among Indian households.

In 2010, the vast majority of CVD-related deaths in the Asia-Pacific Region were due to hypertensive and ischemic heart disease, and stroke \[[@CR1]\]. Risk factors for these conditions can be behavioural, metabolic, (hypertension, hyperglycaemia, abnormal serum lipid levels, or overweight/ obesity), psychological or genetic \[[@CR8]\]. Much of the research on CVD risk factors comes from high income countries, but it has been shown that the various metabolic risk factors are also rising in the Asia Pacific Region \[[@CR9]\]. Evidence from the Framingham Heart Study, the WHO MONICA Project and elsewhere has also shown that behavioural modification can influence metabolic risk factors for CVD \[[@CR10]-[@CR12]\]. Examples of behavioural changes include reduced intake of dietary salt, smoking cessation, trans-fat being replaced by polyunsaturated fat, and increased physical activity \[[@CR8]\].

Why it is important to do this review {#Sec2}
-------------------------------------

Although the causal linkages between primary prevention and CVD-related morbidity and mortality outcomes are well understood, the evidence on the feasibility and cost-effectiveness of such primary prevention interventions is less clear in the Asia-Pacific region, especially in low- and middle-income countries. Studies conducted predominantly in high-income settings suggest that behavioural lifestyle interventions aimed at lowering morbidity and mortality due to CVD are cost-effective when implemented at the population level or when targeting high risk groups \[[@CR13],[@CR14]\]. A recent WHO report also suggests addressing behavioural risk factors due to their cost-effectiveness, and their relative ease and speed of implementation \[[@CR15],[@CR16]\].

However, feasibility and cost-effectiveness tend to be context-specific and difficult to generalise across countries \[[@CR14]\]. One study \[[@CR17]\] modelled population-wide salt and tobacco reduction interventions for several countries and found large variations in government spending associated with implementation (China US\$22 per capita; Vietnam US\$7 per capita; and Philippines US\$14 per capita). To our knowledge no other review has examined the evidence for cost-effectiveness of various CVD lifestyle primary preventions in the Asia-Pacific Region, although a review from 2012 examined pharmaceutical primary preventive interventions in low- and middle-income countries of the region \[[@CR18]\].

Although our focus is on low- and middle-income countries of the region, we included Australia, New Zealand and Japan for three reasons. First, there are migration links between these countries and the rest of the region: nearly two-thirds of all migrants to Australia were from the Asia-Pacific region in 2012-13 and lessons from the Australian experience may apply to specific country settings \[[@CR19]\]. Second there are institutional linkages. For instance, the World Health Organisation's Asia Pacific Observatory on Health Systems and Policies which connects scientific and policy-making bodies throughout the region and acts as a conduit for promoting best-practice health programs throughout the region based on evidence sharing includes both Australia and New Zealand in its membership \[[@CR20]\]. In this context, Australia's tobacco-related policy actions could be of great relevance in much of Asia, including China and India \[[@CR21]\]. Finally, the epidemiological profile of the population in countries of the region will increasingly resemble its more developed counterparts in the region, reflecting rising incomes and convergence in dietary patterns towards western-style foods \[[@CR22]\]. Thus interventions that have previously been considered in the high-income countries of the region may become relevant for their low- and middle-income counterparts in future years.

Methods {#Sec3}
=======

Types of primary prevention interventions {#Sec4}
-----------------------------------------

This review was restricted to primary prevention interventions among adults as long as they targeted at least one of the main behavioural risk factors for CVD. The interventions covered included (but were not restricted to) nutritional programs, physical activity programs (individual/group/community-wide programs), food taxation, salt reduction programs, health promotion advertising, behavioural counselling (dietary, physical activity etc. versus standard care/no primary prevention).

Types of studies {#Sec5}
----------------

Studies were considered for evaluation if they were in the form of \[i\] economic evaluation studies (i.e. cost-effectiveness analyses, cost-utility analyses, cost-benefit analyses) of primary lifestyle/behavioural interventions for CVD using case-control, cohort, cross-sectional or randomised controlled trial methods; \[ii\] simulation studies estimating economic effectiveness for lifestyle/behavioural primary prevention interventions for CVD; \[iii\] studies published in English; \[iv\] studies that were limited to adult populations in Asia and the Pacific.

Studies were excluded if they \[i\] were in the form of letters, abstracts, comments, case reports, editorials, descriptive studies, ecological studies and conference papers; \[ii\] involved non-human subjects; \[iii\] were conducted outside of the Asia-Pacific Region; and \[iv\] did not include information on outcomes (e.g., pure costing studies), or did not include information on intervention costs (only gross economic benefits were estimated).

Search strategy {#Sec6}
---------------

During October 2013 we searched major information sources such as the Cochrane database, Pubmed, Scopus, Database of Promoting Health Effectiveness reviews and the website of the WHO (for the full list of sources and search strategy see Additional file [1](#MOESM1){ref-type="media"}).

Study selection {#Sec7}
---------------

Search results produced titles and abstract for all studies, which were then assessed against our eligibility criteria to determine inclusion for full text review. If an article was rejected, the reason was recorded; if a study was earmarked for inclusion, it was reviewed in its entirety according to an extended standardised eligibility checklist (Additional file [2](#MOESM2){ref-type="media"}).

Data collection process and data items {#Sec8}
--------------------------------------

Pre-determined data was extracted from each of the studies selected for inclusion in the review using a tested data extraction form (Additional file [3](#MOESM3){ref-type="media"}). This data included the year of publication, setting (country and within-country location), target population, study type, economic modelling method, intervention type, health implications, uncertainty considerations made (i.e. sensitivity analysis, discounting), economic outcomes and costs and the perspective used (health sector, societal etc.).

Risk of bias in individual studies (quality review) {#Sec9}
---------------------------------------------------

Full text articles were appraised for quality using the criteria for economic studies' evaluation in Evers et al. \[[@CR23]\]. Studies were ranked, with a 'low-risk' study (++) deemed to have the least risk of bias and considered to be a rigorous economic study (Additional file [4](#MOESM4){ref-type="media"}). The quality criteria took into account the design of the study in terms of the participants, the primary prevention and control alternative; the frequency, duration and intensity of any intervention; measurable outcomes; whether any conflicts of interest were present; and whether ethical approval was obtained. The study design was assessed in terms of the type of evaluation, the basis of this evaluation (e.g., randomised controlled trial, cross-sectional study, simulation modelling, etc.) and the perspective of the study, where a societal perspective is considered the default position. If another perspective was taken an explanation would have to be provided as to why certain costs or effects were not considered or included. If a study period exceeded one year, discounting of future costs would have to be demonstrated. The method for evaluation should have been clearly stated and all relevant outcomes shown, with sensitivity analysis. Studies were ranked according to the NICE scale from ++ to + to -- from lowest to highest risk of bias \[[@CR24]\].

Synthesis of studies {#Sec10}
--------------------

Studies were initially classified by whether they included cost-effectiveness analyses (CEA), where cost is relative to some utility measure (e.g. DALY, QALY, LYS) or another economic evaluation approach (e.g., cost-benefit analysis). For CEA, an assessment of cost-effectiveness was then made for each study or primary prevention intervention within each study. A study was considered very cost-effective if cost per DALY saved was less than GDP per capita, cost-effective if cost per DALY was between 1 to 3 times GDP per capita and not cost-effective otherwise \[[@CR25]\]. GDP per capita for the year in question was obtained from the World Bank Development Indicators Database \[[@CR26]\].

Results {#Sec11}
=======

Study selection and characteristics {#Sec12}
-----------------------------------

The search yielded 16,725 results, of which 87 full texts were retrieved for further assessment. Subsequently, 28 were deemed suitable to be included in the qualitative review using our selection criteria. Primarily studies were excluded due to the research design being incompatible with our criteria and prevention interventions not being lifestyle or behavioural (Figure [1](#Fig1){ref-type="fig"}).Figure 1**Flow diagram of studies in the Asia Pacific Region investigating cost-effectiveness of lifestyle or behavioural interventions for cardiovascular disease primary prevention.**

The studies retrieved for review predominantly used the period 2000-2012 as baseline years, with 4 additional studies \[[@CR25],[@CR27]-[@CR29]\] using 1990 to 1997 as baseline (the studies are summarized in Table [1](#Tab1){ref-type="table"}).Table 1**Study characteristics: location, study design and economic perspectiveStudyCountry/baseline yearIntervention lengthFollow-upStudy populationKey intervention componentsControlPerspective (e.g. health sector)Amarasinghe** \[[@CR30]\]Australia, 20061 Year1 Year18 yrs + in Western Australia, male and female, CVD risk level unknownGP advice for sufficient physical activity (150+ minutes/week) upon random presentation at clinic (6 visits)No GP advice on physical activityHealth Sector**Cecchini** \[[@CR31]\]China, India, 2008Lifetime of population at baseline or up to 100 yrsLifetimeWhole populationInt1 Worksite health promotion; Int2 Compulsory food labelling; Int3 Mass media health promotion campaigns; Int4 Fiscal measures affecting fruit and vegetable and food high in fatNo interventionHealth sector**Cobiac** \[[@CR32]\]Australia, 2003Lifetime of population at baseline or up to 100 yrsLifetimeWhole population (15+ yrs)Int1 Volumetric taxation; Int2 Advertising bans; Int3 Licensing controls on operating hours; Int4 Brief intervention by GP; Int 5 Brief intervention by GP with GP telemarketing and support; Int6 Residential treatment; Int7 Increase legal age; Int8 Drink driving campaigns.Current best practice/'do nothing' (random breath testing present)Health sector**Cobiac** \[[@CR33]\]Australia, 2003Lifetime of population at baseline6 MonthsWhole population (adult, BMI ≥25 kg/m^2^, don't eat at least 7 serves of fruit and vegetables/day, don't get 30+ minutes moderate exercise at least 5x/week)Int1 Lighten up (group counselling for changing physical activity and nutrition patterns); Int2 Weight watchers (low-calorie diet and physical activity advice)No interventionHealth sector**Cobiac** \[[@CR34]\]Australia, 2003Lifetime of population at baselineLifetimeWhole population (15+ yrs at baseline)Int1 Pedometers; Int2 Mass media campaign; Int3 Internet advertising; Int4 GP physical activity prescription program; Int5 Travel smart program to encourage use of active transport; Int6 GP referral to exercise physiologist.Current practiceSocietal and health sectors**Cobiac** \[[@CR35]\]Australia, 2003Lifetime of population at baselineLifetimeWhole population (30 + yrs at baseline)Int1 Govt. incentives for moderate reduction in salt in processed foods by manufacturers and product labelling (voluntary); Int2 Govt. mandate to moderate salt limits in processed foods; Int3 Dietary advice for those at increased risk of CVD; Int4 Dietary advice for those at high risk of CVDNo interventionHealth sector**Cobiac** \[[@CR36]\]Australia, 2003Lifetime of population at baselineLifetimeWhole adult populationInt1 Community-based events, sponsorship, promotion; Int2 Information mail-out (multiple re-tailored); Int3 Information mail-out (multiple tailored); Int4 Information mail-out (tailored); Int5 Individual and group dietary counselling; Int6 Individual dietary counselling; Int7 Telephone counselling and information mail-outNo interventionHealth sector**Cobiac** \[[@CR37]\]Australia, 2008Lifetime of population at baselineLifetimeWhole population (35-84 yrs at baseline, never experienced heart disease or stroke, all CVD risk levels)Community: Int1 Heart health program; Int2 Mandatory reduction of salt in manufacture of bread, cereals and margarines. Individual: Int3 Dietary advice from doctor or dietician; Int4 Referral to more intensive lifestyle program with specialised counselling (≥15% risk of CVD); Int5 Advice from doctor to switch to phytosterol enriched margarine (≥15% risk of CVD)Current best practice ('do nothing')Health sector**Dalziel** \[[@CR38]\]Australia, 20036 Months -- 6 Years1 session --1 YearUnclear -- clinical trials were in adults8 dietary interventionsNo interventionSocietal perspective**Dalziel** \[[@CR39]\]New Zealand, 2000Lifetime (40 years)1 YearAdults 40-79 yrs, M&F, not getting 2.5 hrs physical activity per week (n = 878)Physical activity counselling program (verbal advice and written exercise program by GP or Nurse and telephone exercise specialist follow-up)Best practiceHealth Sector**Elley** \[[@CR40]\]New Zealand, 20001 Year3 MonthsAdults 40-79 yrs, M&F, not getting 2.5 hrs physical activity per week (n = 878)Physical activity counselling program (verbal advice and written exercise program by GP or Nurse and telephone exercise specialist follow-up)Best practiceProgramme funder Perspective**Forster** \[[@CR41]\]Australia, 2003Lifetime of population at baseline or 100 yrs6-12 MonthsAdults 20 yrs + overweight and obeseInt1:Hypertension diet with exercise; Int2:Low-fat dietNo interventionHealth sector**Ha** \[[@CR42]\]Vietnam, 2007Lifetime of population at baseline or up to 100 yrs10 YearsAdult population 30 + years at baseline, all risk levelsInt1: Reduction in salt intake through voluntary manufacturer limits, mass media campaign; Int2:Mass media campaign to reduce cholesterol; Int3:Mass media campaign to reduce tobacco; Int4:Interventions 1-3 combinedNo interventionHealth sector**Higashi** \[[@CR43]\]Vietnam, 2006Lifetime of population at baseline1 SessionAdult population 15 + y at baseline, stratified by i) never smoker, ii) current smoker, iii) ex-smokerBrief physician advice (GP or other health professional) on tobacco cessation (1 min screening and 8 min advice session)Pharmaceutical intervention (NRT patch, NRT gum, Bupropion, Varenicline)Health sector**Higashi** \[[@CR44]\]Vietnam, 2006Lifetime of population at baseline1-10 YearsAdult population 15 + yr at baseline, all risk levelsInt1: Excise tax increase (55-65%); Int2: Excise tax increase (55-75%); Int3: Excise tax increase (55-85%); Int4: Graphic warning labels on cigarette packs; Int5: Mass media campaigns; Int6: Smoking bans in public; Int7: Smoking bans in workplace. All enforced for 10 years.No interventionGovernment perspective (including initial investment in interventions)**Jafar** \[[@CR45]\]Pakistan, 20072 years2 YearsAdult male and females 40 + years, hypertensiveHome health education (HHE) and training of GPs on BP control - Int1 :HHE + trained GP; Int2 :HHE; Int3 : Trained GPCurrent practiceSocietal**Joo** \[[@CR46]\]South Korea, 200712 weeks12 WeeksAdults 20-64 yrs, BMI ≥ 25 kg/m^2^, waist circumference \>90 cm men, 85 cm women, 30 min exercise 4 times/weekProtein-rich oriental diet and either of:- Int1: Public health centre behavioural program; Int2 : Remote behavioural program (internet, SMS)NoneProgram funder perspective**Murray** \[[@CR47]\]South East Asia Region (Indonesia, Sri Lanka, Thailand, Bangladesh, Bhutan, Dem Peop. Rep. Korea, India, Maldives, Myanmar, Nepal), 2000Lifetime of population at baseline or 100 yearsLifetimeWhole populationPopulation interventions for BP and cholesterol control: Int1:Voluntary agreements on salt content with manufacturers; Int2:Legislated salt limits in manufactured food; Int3:Mass media campaign; Int4 : Int2 + Int3Current practiceGovernment (implementation and health sector costs)**Navarro** \[[@CR48]\]Australia, 20051 year1 SessionAdults 18 + yrs at baseline from 10 rural communities in NSW, stratified by drinking behaviourGP screening and brief intervention (1 session)Current best practiceHealth sector**Oldenburg** \[[@CR25]\]Australia, 19901 year1 YearAdult male and female ambulance officers and paramedicsInt1:Health risk assessment (4x over 12 months); Int2 : Risk factor education (4x over 12 months plus reading material); Int3 : Behavioural counselling (risk factor education plus 1 session behavioural counselling); Int 4:Behavioural counselling plus financial incentivesNo interventionProgram funder perspective**Ortegon** \[[@CR49]\]South East Asia Region (Bangladesh, Bhutan, Dem. People's Republic of Korea, India, Maldives, Myanmar, Nepal), 2005Lifetime of population at baseline or up to 100 yrs10 YearsWhole population 15 yrs+Interventions implemented for 10 yearsNo InterventionProgram funder and health sectorInt1: Taxes on tobacco (current excise taxation of 40%); Int2:Raise taxes on tobacco (increased excise taxation to 60%); Int3:Enforce bans on tobacco advertising; Int4:Clean indoor air in public places through legislation and enforcement; Int5:Warning labels on cigarette packs; Int6:Brief advice to help quit; Int7:Counselling to help quit; Int8: Voluntary reduction in salt in industry (15%); Int9: Legislated reduction in salt in industry (30%); Int10:Mass media education on BMI and cholesterol**Pritchard** \[[@CR28]\]Australia, 19921 year1 Year25-65 yr old men and women with one or more of: overweight, hypertension, type 2 Diabetes mellitus6 sessions of counselling on good nutrition and exercise by: Int1: Doctor/dietician; Int2: Dietician onlyNo counsellingProgram funder**Ranson** \[[@CR29]\]East Asia & Pacific, South Asia, 1995Lifetime of participants at baselineLifetimeSmokers 15 + yearsPublic policy control interventions: Int1: 10% price increase; Int2 :Non-price increase, non-pharmaceutical (e.g. mass media)'Do nothing'Program funder (public sector)**Sacks** \[[@CR50]\]Australia, 2003Lifetime of participants at baselineLifetimeWhole population ≥20 years at baselineInt1: Traffic light labelling of food based on nutritional content; Int2 :Junk food tax (10% rise in prices for consumers)No interventionHealth sector (with some industry costs included)**Salkeld** \[[@CR27]\]Australia, 1990Lifetime of participants at baseline1 YearMale and female, selected by GP for at risk of CVDInt1:Video intervention for lifestyle behaviours (n = 270); Int2:Video + self-help booklet (n = 232)Routine care (n = 255)Health sector (govt.)**Shearer** \[[@CR51]\]Australia, 20036 months6 MonthsWhole adult population, smokersInt1:Brief advice by health professional (2x 10 min visits); Int2:Telephone counselling (4x 10 min calls)No interventionProgram funder (govt.)**Snowdon** \[[@CR52]\]Fiji, Tonga, 2006LifetimeLifetimeWhole populationPolicy changes around food price, storage, manufacture, items available for consumption'Do nothing'Govt. (cost offsets excluded)**Zomer** \[[@CR53]\]Australia, 201210 years or death of baseline population10 Years10,000 adults ≥25 yrs with hypertension and metabolic syndrome, no CVD history (based on subsection of AusDiab Study participants)Daily consumption of dark chocolate (500-1000 mg/day)No dark chocolate consumptionHealth sector*Abbreviations*: *Int* Intervention, *CVD* Cardiovascular Disease, *GP* General Practitioner, *NRT* Nicotine Replacement Therapy, *HHE* Home Health Education, *BMI* Body Mass Index, *Govt* Government.

Almost two-thirds of the studies were located within high-income countries of the region (19/28), with 16 in Australia. A large number (22/28) were simulation analyses, while 6 cost-effectiveness assessments were embedded within randomised controlled trial prevention studies \[[@CR25],[@CR27],[@CR28],[@CR40],[@CR45],[@CR46]\]. Only 2 studies \[[@CR28],[@CR46]\] did not include some type of sensitivity analysis for their findings. 18 of the studies were population-based and most studies (23/28) discussed the generalizability of their findings for other populations. Many studies took a government perspective (including costs of the intervention and healthcare cost offsets), with 4 taking a perspective that included the associated household economic burden \[[@CR33],[@CR34],[@CR38],[@CR45]\]. 19 of the 28 studies included DALYs or QALYs as outcomes, based either on CVD outcomes alone, or on CVD outcomes plus cancers and diabetes (and COPD in some cases), for cost-effectiveness analyses. Outcomes in other studies included indicators of changes in risk factors for CVD (e.g., weight reduction, number of smokers quitting, physical activity and systolic BP), and deaths averted.

Given the focus of primary prevention interventions on lifestyle behaviours, it was expected that authors take into account programme compliance rates of participants and their decay over time \[[@CR54]\]. Many studies considered this aspect in the analysis, yet 7/28 did not provide any estimate of the effect of decay \[[@CR28],[@CR37],[@CR45]-[@CR48],[@CR52]\]. Finally, with a few exceptions \[[@CR28],[@CR29],[@CR43],[@CR49]\] that did not itemize costs, most included studies used appropriate costing for interventions and other peripheries.

Risk of bias across studies {#Sec13}
---------------------------

Table [2](#Tab2){ref-type="table"} reports our findings on the risk of bias across the included studies.Table 2**Assessing risk of bias in studies included in the reviewStudySensitivity analysis; discount rate (per annum); perspective (e.g. health sector)Measurement of costs (physical units, valued appropriately, all costs included, itemised)QALY/DALY weights clearly definedAppropriate conclusions based on resultsGeneralisability of study to other settings/ patient groups discussedConflict/s of interest disclaimedEthical issues discussedRisk analysis (++ low risk, + moderate risk, - high risk)Amarasinghe** \[[@CR30]\]Uncertainty of compliance and subsidy rates (10, 20, 25, 50, 75, 100%); N/A; Health Sector✓✓✓✗✓✗**+Cecchini** \[[@CR31]\]Simplified (sd +15% of mean, max and min + -60% mean); 3% (costs and effects); Health Sector✗✗✓✓✓✗**-Cobiac** \[[@CR32]\]Monte Carlo (2000 iterations) 95% CI; 3% (costs and effects); Health Sector✗✓✓✗✓✗**-Cobiac** \[[@CR33]\]Monte Carlo, 95% CI; 3% (costs and effects); Health Sector✗✓✓✗✓✗**-Cobiac** \[[@CR34]\]Monte Carlo (2000 iterations), 95% CI; 3% (costs and effects); Societal and health sectors✓✓✓✗✓✗**+Cobiac** \[[@CR35]\]Monte Carlo, 95% CI; 3% (costs and effects); Health Sector✓✓✓✗✓✗**+Cobiac** \[[@CR36]\]Monte Carlo, 95% CI; 3% (costs and effects); Health Sector✓✓✓✓✓✗**++Cobiac** \[[@CR37]\]Monte Carlo, 95% CI; 3% (costs and effects); Health Sector✓✓✓✓✓✓**++Dalziel** \[[@CR38]\]Uni-variate (effect size, cost, utility, time horizon); 5% (future costs): Societal✗✓✓✓✗✓**+Dalziel** \[[@CR39]\]One-way (1000 simulations); 5% (future costs); Health Sector✗✓✓✓✗✗**++Elley** \[[@CR40]\]Least squares regression model, 95% CI; 5% (costs); Programme Funder✗N/A✗✓✗✓**-Forster** \[[@CR41]\]Monte Carlo (2000 iterations), 95% UI; 3% (costs and effects); Health Sector✓✓✓✓✓✓✗**++Ha** \[[@CR42]\]Monte Carlo (1000 iterations); 3%; Health Sector✗✗✓✓✓✗**-Higashi** \[[@CR43]\]Monte Carlo (2000 iterations), 95% CI; 3% (costs and effects); Health Sector✗✗✓✓✓✗**-Higashi** \[[@CR44]\]Monte Carlo (2000 iterations), 95% UI; 3% (costs and effects); Government (implementation and maintenance)✓✗✓✓✓✗**+Jafar** \[[@CR45]\]Bayesian sensitivity (1000 repetitions), 95% CI; 5% (costs and effects); Societal✓✗✗✓✓✓**+Joo** \[[@CR46]\]No; N/A; Program Funder✓N/A✗✓✗✓**+Murray** \[[@CR47]\]Monte Carlo, multivariate uncertainty analysis (range unclear); 3% (costs and effects); Government (implementation and health sector costs)✗✗✓✓✓✗**-Navarro** \[[@CR48]\]One-way (sensitivity analysis range 39-59%); N/A; Health Sector✓N/A✓✓✓✗**++Oldenburg** \[[@CR25]\]Multivariate; N/A; Program Funder✗N/A✓✓✗✓**+Ortegon** \[[@CR49]\]One way, probabilistic uncertainty analysis; 3% (costs and effects); Program Funder and Health Sector✗✓✗✓✓✗**-Pritchard** \[[@CR28]\]No; N/A; Program Funder✗N/A✓✓✓✓**++Ranson** \[[@CR29]\]Uncertainty around discount rates; 3% (costs and effects); Program Funder (public sector)✗✓✓✓✓✗**+Sacks** \[[@CR50]\]Monte Carlo (2000 iterations), 95% CI; 3% (costs and effects); Health Sector (with some industry costs included)✗✗✓✓✓✗**-Salkeld** \[[@CR27]\]One-way; 5% (costs and effects); Health Sector (govt)✓✓✓✓✗✓**++Shearer** \[[@CR51]\]Multivariate (effectiveness, resource use and costs); N/A; Program Funder (govt.)✗N/A✓✓✗✗**-Snowdon** \[[@CR52]\]Monte Carlo (5000 iterations per country model); probabilistic uncertainty analysis of deaths averted; N/A: Govt. (cost offsets excluded)✗N/A✗✓✗✗**-Zomer** \[[@CR53]\]Monte Carlo (1000 iterations) interquartile range; Uncertainty based on compliance levels; 5% (costs and effects): Health Sector✗✗✗✓✓✗**-***Abbreviations*: *Govt* Government, *CI* Confidence Interval, *UI* Uncertainty Interval, *sd* Standard Deviation.

Only one study \[[@CR53]\] used industry funding but it was specified that there was no conflict of interest with the funding body. 8 of the 28 studies had a potential for conflict of interest based on the lack of a disclaimer, a vague disclaimer or the possibility of stakeholder involvement in the analyses \[[@CR25],[@CR27],[@CR38]-[@CR40],[@CR46],[@CR51],[@CR52]\]. We also compared estimates of primary prevention effectiveness when there was some conflict of interest in the study with estimates of primary prevention effectiveness when studies were deemed to have no conflict of interest. Studies which had some risk of conflict of interest demonstrated a positive effect of the intervention (cost-effective to very cost-effective outcome) about 70 percent of the time, whereas 80 percent of the studies deemed to be without a conflict of interest showed a positive effect of the intervention. Most studies' conclusions followed the results provided, with a few exceptions providing incomplete or selective conclusions relative to the results observed. Overall we deemed 7/28 studies to be at low risk of bias \[[@CR27],[@CR28],[@CR36],[@CR37],[@CR39],[@CR41],[@CR48]\] (with all of these studies conducted in Australia), 12/28 studies to be high risk \[[@CR31]-[@CR33],[@CR40],[@CR42],[@CR43],[@CR47],[@CR49]-[@CR53]\] and the remainder (9/28) as having a moderate risk of bias.

Evidence for cost-effectiveness of primary prevention {#Sec14}
-----------------------------------------------------

Many studies evaluated multiple primary prevention interventions, and some targeted multiple risk factors. For example Jafar et al. \[[@CR45]\] assessed 3 interventions for hypertensive patients: a home-based health education programme delivered by community health workers, a programme delivered by general practitioners, and a combination of the two, compared to no intervention. The interventions targeted diets, physical activity and smoking, and the primary outcomes were systolic blood pressure reduction and DALYs saved. Thus, some studies appear under multiple heads when assessing the impacts of interventions. Table [3](#Tab3){ref-type="table"} summarizes our main findings on economic evaluation.Table 3**Cost-effectiveness of interventionsStudyCurrencyCostsICER (Incremental cost-effectiveness ratio)Cost-effectivenessAmarasinghe** \[[@CR30]\]2003 AUD\$16 million saved on IHD treatmentWhen 100% compliance, \$20 subsidy per GP visit \$810/DALY averted (all causes)Very cost-effective\$18 million saved on stroke treatmentWhen 50% compliance, \$25 subsidy rate, \$11,000/DALY averted (all causes)**Cecchini** \[[@CR31]\]2005 US\$At 20 yrs, compared to control -- Int1 China \$7785/DALY averted, India \$6151/DALY averted; Int2 China \$71/DALY averted, India \$952/DALY averted; Int3 China \$7188/DALY averted, India \$15552/DALY averted; Int4 China cost-saving, India cost-savingInt 1 Cost-effective in China, not cost-effective in India; Int 2 very cost-effective in China, cost-effective in India; Int 3 very cost-effective in China, not cost-effective in India; Int4 very cost-effective**Cobiac** \[[@CR32]\]2003 AUDCompared with current best practice:Int1-5, 7-8 very cost-effective; Int 6 not cost-effectiveInt1 Dominant; Int2 Dominant; Int3 \$3300/DALY averted; Int4 \$6800/DALY averted; Int5 \$10,000/DALY averted; Int6 \$190,000/DALY averted; Int7 Dominant; Int8 \$14000/DALY averted**Cobiac** \[[@CR33]\]2003 AUDCompared to 'do nothing'Cost-effectiveInt1 \$130,000/DALY averted; Int2 \$140,000/DALY averted**Cobiac** \[[@CR34]\]2003 AUDCompared to 'do nothing' (medians)Int 1-5 very cost-effective; Int 6 cost-effectiveInt1 Dominant; Int2 Dominant; Int3 \$3000/DALY averted; Int4 \$11,000/DALY averted; Int5 \$18,000/DALY averted; Int6 \$79000/DALY averted**Cobiac** \[[@CR35]\]2003 AUDCompared to 'do nothing' :Int1 and 2 cost-effective; Int 3 not cost-effective; Int4 unlikely to be cost-effectiveInt1 Dominant; Int2 Dominant; Int3 \$260000-\$390000/DALY averted; Int4 160000-250000/DALY averted**Cobiac** \[[@CR36]\]2003 AUDCompared to 'do nothing', at 1 yr (assumed 50% decay in effectiveness after implementation):Int 1-4 very cost-effective; Int 5 and 6 not cost-effective; Int7 cost-effectiveInt1 Dominant; Int2 \$8600/DALY averted; Int3 \$12000/DALY averted; Int4 \$27000/DALY averted; Int5 \$280000/DALY averted; Int6 \$950000/DALY averted; Int7 \$84000/DALY averted**Cobiac** \[[@CR37]\]2008 AUDCompared to 'do nothing':Int1 and 2 very cost-effective; Int 3 and 4 cost-effective; Int 5 not cost-effectiveInt1 Dominant (Dominant to Dominant); Int2 \$44000/DALY averted (\$19000-\$100000/DALY averted); Int3 \$1000000/DALY averted (\$610000-2400000/DALY averted); Int4 \$1400000/DALY averted (\$960000-2500000/DALY averted); Int5 \$3200000/DALY averted (\$1900000-5900000/DALY averted)**Dalziel** \[[@CR38]\]2003 AUDCompared to control: \$46/QALY to \$19800/QALY for all 8 interventionsVery cost-effective**Dalziel** \[[@CR39]\]2001 NZ\$Compared to control, at 40 year time point:Very cost-effectiveFor intervention implemented 1 year, effects lasting 4 years: \$2053/QALY gained; Effects lasting 5 years: \$1663/QALY gained; Effects lasting 10 years: \$1160/QALY gained**Elley** \[[@CR40]\]2001 NZ\$At 12 months, compared to control: \$1756 for 1 adult to move from a sedentary to active state; Program cost \$170.45 per patient per yearInconclusive**Forster** \[[@CR41]\]2003 AUDCompared to control: Int 1 \$12000/DALY averted (cost saving -\$68000/DALY averted); Int 2 \$13000/DALY averted (cost saving -\$130000/DALY averted)Very cost-effective**Ha** \[[@CR42]\]2007 VNDInt1 1945002/DALY averted; Int2 12324059/DALY averted; Int3 2416075/DALY averted; Int4 2211140/DALYCompared to control: All interventions DominatedVery cost-effective**Higashi** \[[@CR43]\]2006 VND1742000/DALY averted (I\$ 543/DALY averted) physician adviceCompared to control: All pharmaceuticals dominated by physician advice.Physician advice very cost-effective; pharmaceutical interventions not cost-effective**Higashi** \[[@CR44]\]2006 VNDCompared to control: All interventions dominateVery cost-effectiveInt1 8600VND/DALY averted (3400, 20100);Int2 4200VND/DALY averted (1700, 9900); Int3 2900VND/DALY averted (1100, 6700); Int4 500VND/DALY averted (300,1200); Int5 78300VND/DALY averted (43700, 176300); Int6 67900VND/DALY averted (28200-332000); Int7 336800VND/DALY averted (169300, 822900)**Jafar** \[[@CR45]\]2007 US\$Compared to no intervention: Int 1\$23/mmHg (\$7-\$101/mmHg); Int 2 Dominated (dominated to 730/mmHg); Int 3 \$206/mmHg (Dominated to \$807/mmHg)Inconclusive**Joo** \[[@CR46]\]2007 US\$Public health int \$976/person to reach target weight; Remote int. \$1637/person to reach target weightInconclusive**Murray** \[[@CR47]\]I\$ 2000Int 1 \$37/DALY averted; Int2\$19/DALY averted; Int3 \$14/DALY averted; Int4 \$17/DALY averted (personal interventions \$36-90/DALY)Int 2 compared to Int3 \$14/DALY averted; (Int 2 to Int 4) compared to (Int 3 to Int4) \$20/DALY avertedVery cost-effective**Navarro** \[[@CR48]\]2005-2006 AUDCompared to 'do nothing': 10% increase in screening rate \$217/risky drinker reducing alcohol consumption; 20% increase \$205; 100% increase \$216Inconclusive**Oldenburg** \[[@CR25]\]1990 AUDInt3 (only intervention which reached the maintenance stage of behavioural intervention) \$22.06/unit of CVD risk reductionInconclusive**Ortegon** \[[@CR49]\]I\$ 2005Compared to no intervention: Int1 \$116/DALY averted; Int2 \$87/DALY averted; Int3 \$187/DALY averted; Int4 \$162/DALY averted; Int5 \$195/DALY averted; Int6 \$958/DALY averted; Int7 \$1179/DALY averted; Int8 \$197/DALY averted; Int9 \$901991/DALY averted; Int10 \$191/DALY avertedInt 1-5, 8, 10 very cost-effective; Int6 not cost-effective in Myanmar, cost-effective in Bangladesh, Dem Rep Korea, India, very cost-effective Bhutan, Maldives; Int7 not cost-effective in Myanmar or Nepal, cost-effective in Bangladesh, India, Dem Rep Korea, very cost-effective in Bhutan and Maldives; Int9 not cost-effective**Pritchard** \[[@CR28]\]1993-4 AUDCompared to control: Int 1 \$9.76/extra kg lost (12% reduction in BP); Int 2 \$7.30/extra kg lost (7% reduction in BP)Inconclusive**Ranson** \[[@CR29]\]1997 USDCompared to control: Int 1: East Asia & Pacific \$2-50/DALY averted, South Asia \$1-33/DALY averted; Int 2: East Asia & Pacific \$25-510/DALY averted, South Asia \$16-326/DALY avertedInt 1 Very cost-effective; Int 2 cost-effective to very cost-effective**Sacks** \[[@CR50]\]2003 AUDCompared to 'do nothing': Int 1 Dominant (\$30/DALY averted, 95% CI 20-40); Int 2 Dominant (\$1800/DALY averted, 95% CI 1360-2170)Very cost-effective**Salkeld** \[[@CR27]\]1994 AUDCompared to routine care, both interventions not cost-effective or effective (no significant change in risk); Except for Int 1 for high risk males \$39440/LYS and \$29574/QALYInt 1 for high risk males very cost-effective**Shearer** \[[@CR51]\]2003 AUDBrief advice: \$1910/quitter (\$1273-3820); Telephone counselling: \$606/quitter (\$505-757)Inconclusive**Snowdon** \[[@CR52]\]2006 Fiji dollar (FJD)At 1 year Most effective: Tonga -- Ban on sale of all fatty meats TOP 30974/6.61 deaths averted; Fiji -- cool storage available at all marketsInconclusive2006 Tongan Pa'anga (TOP)FJD1600149/65.54 deaths averted; Lowest costs: Tonga -- removal of licensing requirements for roadside vendors selling local produce TOP0/death averted; Fiji- import duty (15%) added to all oils FJD396/17.43 deaths averted**Zomer** \[[@CR53]\]2012 AUD100% compliance: \$50,000/LYSVery cost-effectiveNB. All studies are cost-effectiveness analyses. Abbreviations: CEA -- Cost-Effectiveness Analysis; FJD -- Fijian Dollar; TOP -- Tongan Pa-anga; AUD -- Australian Dollar; DALY -- Disability-Adjusted Life Years; QALY -- Quality-Adjusted Life Years; LYS -- Life Years Saved; CI -- Confidence Interval; USD -- United States Dollar; I\$ - international dollars; VND -- Vietnamese Dong; mmHg -- millimetres of mercury; NZ\$ - New Zealand Dollar; Int -- Intervention; yrs -- years; ICER -- Incremental Cost-Effectiveness Ratio.

Tobacco control {#Sec15}
---------------

7 studies dealt with tobacco control, of which 5 were in low- and middle-income countries \[[@CR42]-[@CR45],[@CR49]\], 1 in a high-income country \[[@CR51]\], and one in countries of all income levels \[[@CR29]\]. Two studies \[[@CR45],[@CR51]\] did not demonstrate cost-effectiveness because their outcomes were other than QALYs or DALYs, namely the numbers of individuals who quit smoking and reduction in systolic BP \[[@CR45],[@CR51]\]. 3 studies demonstrated interventions that were very cost-effective \[[@CR42]-[@CR44]\] with \[[@CR43]\] investigating the cost-effectiveness of brief physician advice (general practitioner \[GP\] or other health professional) on tobacco cessation (1 min screening and 8 min advice session); \[[@CR44]\] analysing excise tax increases (55%-65%, 55%-75%, 55%-85%), graphic warning labels on cigarette packs, mass media campaigns, smoking bans in public and smoking bans in the workplace; and \[[@CR42]\] looking at a mass media campaign to reduce tobacco use. 2 studies assessed interventions that ranged from not cost-effective to very cost-effective depending on location and intervention type \[[@CR29],[@CR49]\]. In study \[[@CR29]\], compared to 'do nothing', a 10% price increase (55%-65%) in cigarettes was very cost-effective, and mass media interventions ranged from cost-effective to very cost-effective (from \$25-510/DALY averted in East Asia & Pacific and \$16-326/DALY averted in South Asia). In study \[[@CR49]\] which used simulation modelling, increasing excise taxes on tobacco, bans on tobacco advertising, legislation and enforcement for clean indoor air in public places, and warning labels on cigarette packs were all very cost-effective in South and Southeast Asia.

Alcohol reduction {#Sec16}
-----------------

We found only 2 studies that evaluated cost-effectiveness of alcohol reduction primary prevention interventions \[[@CR32],[@CR48]\], both in Australia. Study \[[@CR32]\] reported results ranging from not cost-effective (residential treatment for alcohol reduction) to very cost-effective (volumetric taxation, advertising bans, licensing controls on operating hours, brief primary prevention by GP, brief primary prevention by GP with telemarketing and support for GP recruitment to program, increased legal age of alcohol consumption from 18 to 21 years and mass media drink driving campaign). This study considered healthcare cost offsets in assessing cost-effectiveness. Study \[[@CR48]\] was a cost-effectiveness analysis of an intervention consisting of screening by a GP and brief intervention if necessary (one appointment) among high-risk drinkers in a rural community in Australia. Outcomes were a reduction in high-risk drinking and the study estimated costs ranging from \$175-\$300 per high risk drinker moving to a low-risk status. However, no DALY or QALY outcomes were reported so a direct assessment in terms of the criteria of cost-effectiveness used in this review was not possible.

Salt intake control {#Sec17}
-------------------

We found 4 studies on salt control primary prevention interventions (Table [1](#Tab1){ref-type="table"}), 2 in Australia \[[@CR35],[@CR37]\], one in Vietnam \[[@CR42]\], and one in a set of South East Asian countries \[[@CR49]\]. In 2 studies, interventions ranged from being not cost-effective to cost-effective/very cost-effective depending on intervention type or setting \[[@CR35],[@CR49]\], and 2 studies \[[@CR37],[@CR42]\] found the interventions to be very cost-effective. In study \[[@CR35]\] incentives from government for moderate reduction in salt in processed foods and product labelling by manufacturers, and a government mandate for manufacturers to moderate salt limits in processed foods were cost-effective relative to 'doing nothing'; and individual dietary advice for those at increased/high risk of CVD was not cost-effective. In study \[[@CR49]\], voluntary reduction in salt by the industry (15%) was found to be very cost-effective; and a legislated 30% reduction in salt in industry also ranged from cost-effective to very cost-effective, relative to doing nothing. In \[[@CR37]\], compared to 'doing nothing', the mandatory reduction of salt in the manufacture of bread, cereals and margarines was found to be very cost-effective. In \[[@CR42]\], a reduction in salt intake through voluntary manufacturer limits and a mass media campaign were very cost-effective.

Physical activity/diet control {#Sec18}
------------------------------

Roughly three-fourths of the studies (20/28) examined diet and or physical activity-based primary preventions. Of these, 5 \[[@CR31],[@CR42],[@CR45],[@CR47],[@CR52]\] were in low- and middle-income countries. Of the 15 studies in high-income countries, 12 studies were conducted in Australia. The most common form of prevention evaluated was counselling (18 studies), although a few studies also evaluated legislation, taxation and mass media-based interventions. All 6 randomised controlled-trial (RCT)-embedded studies included in this review were in the physical activity/diet category, and of these only 1 was conducted in a middle-income country, Pakistan \[[@CR45]\].

The studies in low- and middle-income countries covered a variety of primary prevention interventions. A study in Fiji and Tonga \[[@CR52]\] examined the impact of tax interventions (lowering import duties on fruits and vegetables, raising import duties on fatty oils, removal of import duty benefits for processed meats), legislation (ban sales of fatty meats and fatty processed foods) and enhancing cool storage for fruits, vegetables and fish, concluding that tax policies and legislation were likely to be much more cost-effective (in terms of deaths averted) than expansion of storage facilities. However, outcomes were not expressed in DALYs or QALYs. The study for Pakistan \[[@CR45]\] was also difficult to assess from a cost-effectiveness perspective as the outcome was systolic BP. Study \[[@CR48]\] used mathematical modelling together with effectiveness data from mostly high-income countries to assess the cost-effectiveness of 7 programmes directed to diets and physical activity in 6 middle-income countries, of which 2 (China and India) were in the Asia-Pacific region. The programs evaluated were school-based primary preventions, worksite primary preventions, mass media campaigns, tax policies (affecting prices for fruits, vegetables and foods rich in fat), GP counselling, regulation of food advertising and food labelling. Regulation of food advertising, food labelling and tax policies ranged from cost-effective to very cost-effective in both China and India. In China, moreover, worksite primary preventive interventions and mass media campaigns were assessed to be very cost-effective over a long (50-year) horizon. However, other interventions were not cost-effective in either country. In Vietnam, a mass media campaign aimed at reducing cholesterol \[[@CR42]\] was assessed to be very cost-effective, although other than salt intake it was not clear if any other lifestyle factors were targeted by the intervention. A mass media campaign targeting BP and cholesterol control was also found to be very cost-effective in \[[@CR47]\] in Southeast Asian countries.

In studies conducted in high income countries (Australia, New Zealand and South Korea), 5 either did not explicitly assess cost-effectiveness or used outcome measures that were not expressed in DALYs or QALYs \[[@CR25],[@CR28],[@CR40],[@CR46],[@CR53]\]. Study \[[@CR46]\], set in Korea, concluded that it was more cost-effective to educate individuals about dietary and lifestyle changes to lower weight than to do so remotely via the internet; study \[[@CR40]\] set in New Zealand concluded that GP advice and prescription for physical activity with telephone follow-up by an exercise specialist increased physical activity among 40-79 year olds at a 'reasonable cost'; study \[[@CR28]\] set in Australia concluded that nutritional counselling to overweight or hypertensive patients lowered weight at a rate of \$7-\$10 of programme costs per lost kilogram; another study \[[@CR25]\] concluded that behavioural counselling was more cost-effective in lowering CVD risk factors than strategies focused on risk-factor education among individuals or behavioural counselling plus financial incentives; and study \[[@CR53]\] also set in Australia, found an intervention promoting dark chocolate consumption was very cost-effective.

The remaining 10 studies were set in Australia (1 in New Zealand). Of these, a significant number focused on counselling, with and without GPs, and these interventions were generally cost-effective. In study \[[@CR30]\], GP advice for sufficient physical activity upon presentation at a clinic was compared to no advice and found to be cost-effective/very cost-effective depending on patient compliance rates. In study \[[@CR27]\] GPs were provided with a video and an instructional guide to assess risk factors and to plan risk factor behaviour change and patients also received a video on lifestyle behaviours and risk factor assessment. In addition, a small group received a self-help booklet. Video-based interventions were cost-effective or very cost-effective for high-risk males, but were not cost-effective for other population subsets. In study \[[@CR37]\], dietary advice from doctor or dietician or referral to more intensive lifestyle program with specialised counselling (for those with ≥15% risk of CVD) were found to be cost-effective compared to doing nothing. In study \[[@CR39]\] a physical activity counselling program in New Zealand implemented by a GP or nurse with telephone follow-up was found to be very cost-effective compared to existing practice. In study \[[@CR33]\], group counselling for changing physical activity levels and nutritional patterns, and a low-calorie diet with physical activity advice were found to be cost-effective compared to no intervention although health gains were overall quite low. On the other hand \[[@CR34]\] found GP physical activity prescription programs to be very cost-effective and GP referral to an exercise physiologist to be cost-effective. Only one study \[[@CR36]\] found individual and group counselling to be not cost-effective. Study \[[@CR36]\] also assessed community-based primary prevention including sponsorship and promotion for fruit and vegetable consumption, information mail outs, all of which were very cost-effective.

Among other primary prevention interventions, study \[[@CR50]\] found junk food taxes and food labelling targeted at Australia's adult population to be individually very cost-effective. Study \[[@CR34]\] assessed interventions for increasing physical activity, finding the use of pedometers, a mass media campaign, internet advertising and a program to encourage the use of active transport to be very cost-effective; study \[[@CR38]\] examined 8 diet programs and found all to be very cost-effective; and finally, in study \[[@CR41]\], a hypertension diet combined with exercise and a low-fat diet were compared to no intervention and both were very cost-effective, although the overall health benefits were small.

Several of these studies addressed BMI as a cardiovascular risk factor. Despite BMI by itself not being a reliable predictor of CVD, in the absence of other measures such as systolic BP and diabetes, it offers some indication that other risk factors for CVD may be present, as determined in a recent, comprehensive Lancet study \[[@CR55]\]. Weight loss studies included in this review follow this line with weight gain considered an intermediate risk factor for CVD with studies \[[@CR27],[@CR33],[@CR34],[@CR37],[@CR39],[@CR41],[@CR52]\] modelling QALYs or DALYs based on, for example, the relative risk of cardiovascular (and other) disease when at a particular weight. Studies \[[@CR28],[@CR40],[@CR46]\] use weight loss as the direct outcome.

Discussion {#Sec19}
==========

We find first that multiple tobacco control interventions, particularly taxes on tobacco, advertising restrictions, warning labels, mass media campaigns and GP consultations were cost-effective to very cost-effective. Second, available studies show that alcohol taxation, advertising restrictions, mass media campaigns against drunk driving and GP-based primary preventions range from cost-effective to very cost-effective, although in this case, the studies are limited to Australia. Third, voluntary manufacturer limits, or mandated or incentivized reduction in salt in processed foods were very cost-effective. However, dietary advice on salt intake for individuals at high risk of CVD was not cost-effective. Fourth, regulation of food advertising, food labelling and taxes on fatty foods/oils are very cost-effective, although the evidence on worksite primary prevention was unclear. Studies, primarily from developed countries in the region, also show that dietary and physical activity counselling through health personnel (with some follow up) is cost-effective. Community-based primary prevention on diet and physical activity were also found to be cost-effective but their benefits were small.

Unfortunately we also find a serious shortage of information on cost-effectiveness for primary lifestyle prevention related to CVD in the Asia-Pacific region. Only 28 studies met our inclusion criteria, covering various lifestyle and behavioural interventions for primary prevention of CVD. A large number of studies analysed in this review were conducted in developed countries of the region, mainly Australia. Only 8 studies were conducted exclusively in low- or middle-income countries of the Asia Pacific Region (Fiji and Tonga; China and India; Pakistan; Vietnam) so that generalizing our findings on cost-effectiveness of primary prevention interventions to the broader region is difficult. Only one study covered a broad cross-section of countries in the region, low- and high-income, and was limited to tobacco control. And a number of studies did not use DALYs or QALYs as outcomes.

Overall 20/28 of the studies demonstrated cost-effectiveness of an intervention, but we cannot rule out publication bias skewing our results towards including studies demonstrating cost-effectiveness. However, the share of studies reporting (cost) effectiveness is similar to comparable reviews in the field \[[@CR56]\].

With the exception of \[[@CR40],[@CR41]\] studies included in this review generally rely on short-term effects of interventions to construct cost-effectiveness estimates. Short-term effects can be misleading if there is relapse in behaviour, as in interventions targeting weight loss or smoking or, when intervention is at the population level, there are saturation effects \[[@CR57]\]. In particular, mathematical modelling the effects of an intervention over the lifetime of an individual are susceptible to this problem given their estimates of economic impacts rely on modelling of behavioural change beyond the intervention period \[[@CR27],[@CR33],[@CR38]-[@CR44],[@CR49]\]. In addition, RCT-based analyses sometimes rely on conditions that are unlikely to be replicated in other real life settings. Sensitivity analyses can address this to an extent and many of the studies included in this review do include analyses that allow for variation in the estimates of program effectiveness. The sensitivity analyses took various forms, such as allowing for decay in behavioural interventions over time or variations in compliance rates, or in some cases, varying rates of program effectiveness. However, it is difficult to evaluate how effective these sensitivity analyses were in capturing uncertainty about the full range of outcomes that were possible and/or long-term program effects. For those studies which were modelled for over a year, discount rates were similar, with most authors discounting both costs and effects by 3 to 5 percent annually. Another limitation is that several studies did not provide a clear definition of the DALY or QALY weighting used in their analysis \[[@CR31],[@CR42]-[@CR45],[@CR47],[@CR50],[@CR53]\].

Primary prevention interventions also varied considerably in the studies considered. Interventions associated with tobacco control, alcohol reduction, physical activity/diet control and salt control can broadly be divided into counselling, legislation and mass media. Yet, in their implementation, the interventions evaluated varied by the age and occupational group of the population targeted, gender, risk level for CVD; the length of intervention; or the implementing body be it general practitioners, legislators or researchers. Thus, for counselling-mediated physical activity and diet primary prevention, the target population varied from the whole population \[[@CR47]\], to those 20 years or older who were also overweight or obese \[[@CR41]\] to those who were 18 years or older and ambulance officers \[[@CR25]\].

In consequence it is difficult to aggregate the cost-effectiveness findings of individual studies, say through meta-analysis based on results from high quality studies. Much of the evidence for effectiveness, even when applied to low- and middle-income countries in the region, has come from high-income countries, some from outside the Asia-Pacific. The cost data, derived from the WHO-CHOICE model in some of the studies, conforms to a standardized approach that may not be suited to the considerable heterogeneity across health systems in the region. Moreover the assessment of costs was variable, with some studies limited to costing the primary prevention alone, others to taking account of the costs of healthcare use associated with the primary prevention and a few also including household costs.

Finally, the review makes clear the need to have graded cost-effectiveness data for multiple interventions and standardized methods for estimating costs and outcomes for individual countries in the region to guide policy choices. Australia is the only country of the Asia-Pacific Region with a developed evidence base and a relative standardisation of methods \[[@CR32]-[@CR37]\], and could serve as a benchmark for similar studies elsewhere in the region.

Conclusion {#Sec20}
==========

Although there is a large international literature on the effectiveness and cost-effectiveness of primary prevention interventions targeting lifestyle factors for CVD, a closer examination points to a very limited literature in the Asia-Pacific Region. Even this limited literature is characterized by variations in the interventions evaluated across countries and use of dissimilar methodologies, and has its major focus on high-income countries in the region. This constitutes a major gap in the literature at a time when NCDs are acquiring increasing significance in the region. As countries turn towards universal healthcare coverage, policymakers will need high quality advice about efficient strategies regarding NCDs, particularly those focusing on prevention, to avoid burdening health systems with large numbers of individuals with chronic conditions that are expensive to treat.
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